Top Stories News

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Utilising the current data environment and its data pools for the benefit of advancing research.

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

End-to-end industrial production of innovative medical technology products.

2019 will mark Uniplast's debut at this year's edition of CPHI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

With only a month to go, it really is too late to start trying to develop an in-house solution.

Eight of the top ten pharma nations reporting improving market conditions.

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Therapeutic ADC market expected to reach $4 billion by 2023.

Companies new to CPHI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

CPHI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.

With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?

Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.

One company's positive approach to Brexit preparations, despite the lack of definition.

The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.

To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".

FDF launches at CPHI Korea as country set to become regional hub.

Packaging technology is not a core Bosch business.

Experts warn bio industry needs to do more to create a sustainable pipeline of talent.

2018 event prepares for surge in international attendees as MAH nears national rollout.

Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.

Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.

Global Drug Supply, Safety and Traceability Report reveals disparity in industry’s readiness to comply with track and trace regulations in the US and EU.

NIH-funded study finds omega-3 fails to yield beneficial results in the clinic.

Global analysis will rank each major biomanufacturing country’s market growth potential, innovation and competitiveness.

Manufacturing high potency drugs - the challenges and innovations to mitigate the risks.

Customers cite network connectivity, efficiency of partner onboarding, and seamless data exchange as significant differentiators.

Customers to have the option of one partner from concept to market for their encapsulated drug products

Gaining GLP/GMP accreditation to provide greater assurance of data integrity for clients looking to take their compounds to IND.

Screening for new marine-derived functional ingredients and bringing new patented products to the market.

Packaging innovation shows a clear focus on patient compliance and ease-of-use.

What does a good supplier look like? Andrew Ramage, Microbiology Product Specialist at Cherwell Laboratories, advises how to take the guesswork out of the search.

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

A summary and highlights of new drug therapy approvals and other drug therapy advances in 2017 by FDA's CDER.

Total cost base to be reduced by $3 billion by the end of 2019.

Drug trials provide mind-blowing results.

MSD's announcement to establish UK Discovery Centre in London an 'endorsement' of the government's Industry Strategy.

Controlled-release technologies will continue to be focal point, whereas techniques to improve solubility are likely to gain popularity.

Company's decision affects approximately 225 staff, specialised in tablet manufacturing, and in sachet and stick pack filling, primarily for powders and granules.

19 winners chosen from 200 entries, received from nearly 30 countries worldwide.

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee.

CDMO, Micro-Sphere partners with German machine manufacturer Harro Höfliger for the latest step in its 21 million CHF (€19 million) investment into its facility in Switzerland.

The importance of ensuring a facility has the right capabilities when selecting a CMO to handle high potency ingredients.

Warning letter cites Meridian Medical Technologies' failure to thoroughly investigate multiple serious component and product failures of EpiPen products.

In connection with the $60 million settlement, the company has also resolved several private whistle-blower cases related to the government's investigation.

Mylan will reclassify EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products effective as of 1 April 2017.

Bolt-on acquisition adds value to other areas of Lonza’ business, including Health & Nutrition ingredients and excipients.

AI thought to have massive potential to reduce the cost associated with the discovery of new drugs.

Collaborations result in development of Corning Valor Glass.

Company announces investments, the sale of several products and a proposal to close a UK manufacturing site.

The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.

Discontinuation due to the vaccine supplier’s (GSK) decision to discontinue global production.

Status marks the company as the first multi-site excipient supplier to achieve global EXCiPACT accreditation across its production facilities.

New production method for solid dispersions of docetaxel and paclitaxel.

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

Settlement provides Mylan with global licenses for its trastuzumab product.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.

NTC Pharma expands its product portfolio with a new food supplement containing iron pyrophosphate microencapsulated in liposomal form, Turbofer orosoluble granules.

The molecule, which is a PPMO, will likely be ready for testing in humans in about 3 years.

Therapies targeted at this novel mechanism have the potential for disease-modification because they will address the genetic root cause of AD.

Ariad stockholders to receive $24.00 per share in cash.

Authorized generic offered at more than 50% below wholesale acquisition cost of EpiPen auto-injector.

Acquisition will make Lonza a fully integrated solutions provider in oral delivery technologies and active ingredients to the consumer healthcare and nutrition markets.

Company will also close its Hopewell, New Jersey site and will not renew its lease at the Lake Union Steam Plant site in Seattle, Washington.

Pharma giant says it complied with established competition law.

Lilly's solanezumab fails to meet primary endpoint of Phase III study.

Bococizumab deemed unlikely to provide value to patients, physicians, or shareholders.

New treatment elicits two-pronged immune response that destroys tumors in mice.

Inflectra will be the first biosimilar monoclonal antibody (mAb) to be available in the US.

The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel.

Company to continue to operate as one company with two distinct and complementary businesses to retain operating strength and financial flexibility.

Comprehensive roadmap lays out key commitments the pharmaceutical companies pledge to deliver by 2020 to reduce antimicrobial resistance.

Investment in advanced manufacturing of new respiratory and biopharmaceuticals portfolio.

This milestone marks the sixth Breakthrough Therapy Designation for Opdivo.

Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020.

Brings more than three decades of leadership and operations experience in healthcare.

Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.

New tablet attaches to the lining of the GI tract, resists being pulled away.

The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.

The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine.

Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020.

World’s largest pharma event sees record exhibitor numbers in Madrid.

As a result of the combination with Allergan and subsequent integration of the two companies, Pfizer now expects to make a decision about a potential separation of the combined company's innovative and established businesses by no later than the end of...

Transactions are consistent with the evolution of BMS’s strategic focus, including the decision to discontinue its discovery efforts in virology announced in June.

Company’s preliminary investigation indicates tha the incidents of out-of-place softgel capsules in several product batches could be related to a deliberate action by one or more individuals.

Perrigo will immediately commence its previously announced $2 billion repurchase of Perrigo shares and plans to complete $500 million of the planned repurchase by the end of 2015.

Exiting four sites to optimise capacity utilisation will affect approximately 1,200 positions.

The vaccines division of Sanofi presents at the World Vaccine Congress in Spain.

New building to feature collaboration-focused workspace.

Corporate restructuring to result in an 11% workforce reduction.

Phase III trial terminated due to insufficient efficacy.

Prize awarded for mapping, at a molecular level, how cells repair damaged DNA and safeguard the genetic information.

The FTC filed its amicus brief in a private antitrust action in which Mylan Phamraceuticals Inc. alleges that Warner Chilcott PLC/Mayne Pharma Group maintained a monopoly in the market for its antibiotic Doryx by suppressing generic competition through...

The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.